Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)
Blood（2021）
摘要
Background:
更多查看译文
关键词
multiple myeloma,relapsed/refractory multiple myeloma,low dose dexamethasone,proteasome inhibitor,immunomodulatory agent
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要